微芯生物不超9.5亿定增获上交所通过 国投证券建功

Core Viewpoint - Microchip Biotech (688321.SH) has received approval from the Shanghai Stock Exchange for its application to issue A-shares to specific investors, pending final approval from the China Securities Regulatory Commission (CSRC) [1] Fundraising Details - The total amount to be raised through the issuance is capped at 950 million yuan, with net proceeds allocated to innovative drug research and development, the first phase of the Pengzhou Microchip original drug manufacturing base, and to supplement working capital [1][2] - The total investment for the projects is approximately 1.025 billion yuan, with specific allocations of 350 million yuan for innovative drug R&D, 350 million yuan for the manufacturing base, and 250 million yuan for working capital [2] Issuance Structure - The issuance will not exceed 58,125,305 shares, representing a maximum of 30% of the total share capital prior to the issuance [3] - The pricing mechanism will be based on 80% of the average trading price of the company's A-shares over the 20 trading days preceding the pricing date [3] Subscription Conditions - The issuance will be open to no more than 35 specific investors, including qualified institutional investors such as securities investment funds, securities companies, trust companies, and qualified foreign institutional investors (QFII) [2][4] - Shares subscribed by these investors will be subject to a six-month lock-up period post-issuance [4] Shareholding Structure - As of the date of the fundraising prospectus, the controlling shareholder and actual controller is Xianping Lu, who holds 5.45% of the shares directly, with a total control of 22% when considering associated entities [5] - Post-issuance, Xianping Lu's control will decrease to 19.25%, but he will remain the controlling shareholder [5] Underwriting Information - The lead underwriter for this issuance is Guotou Securities Co., Ltd., with representatives Hu Jiabin and Song Qian overseeing the process [5]